LEADER 00000cam a22005897a 4500 
001    ocm00000004 
005    20130620121302.0 
008    110616s2011    enka     b    000 0 eng   
010      2011932235 
016 7  101568949|2DNLM 
020    9780123918758|qhardback 
020    0123918758|qhardback 
035    (OCoLC)ocn794001624 
035    (OCoLC)794001624 
035    572409 
040    NLM|beng|cNLM|dDLC|dWRM|dOCLCO 
042    nlmcopyc|alccopycat 
049    RIDM 
050 00 RA410.5|b.S26 2011 
082 04 615.7|222 
090    RA410.5 .S26 2011 
100 1  Sánchez-Serrano, Ibis.|0https://id.loc.gov/authorities/
       names/no2011134682 
245 14 The world's health care crisis :|bfrom the laboratory 
       bench to the patient's bedside /|cby Ibis Sánchez-Serrano.
250    1st ed. 
264  1 London ;|aWaltham, MA :|bElsevier,|c2011. 
300    xxiii, 271 pages :|billustrations ;|c24 cm. 
336    text|btxt|2rdacontent 
337    unmediated|bn|2rdamedia 
338    volume|bnc|2rdacarrier 
490 1  Elsevier insights 
504    Includes bibliographical references (pages 269-271). 
505 0  Part I: The Global Health Care Crisis.-- 1. The world's 
       health care crisis : the United States' leadership -- The 
       US Health Care Crisis -- The US Health Care System -- 2. 
       The health care crisis in other parts of the world -- The 
       French Health Care System -- The UK Health Care System -- 
       Private insurance use in Europe -- Other industrialized 
       nations -- The developing world: in search of hope -- The 
       pharmaceutical industry -- Part II: Understanding the 
       biopharmaceutical business.  -- 3. A brief commercial 
       history of the biopharmaceutical industry up to the year 
       2000 -- The pharmaceutical industry begins -- The Swiss 
       pharmaceutical industry -- The English pharmaceutical 
       players -- The United State enters the scene -- Impact of 
       World War I (1914-18) -- Impact of World War II (1939-45) 
       -- The Biotechnology Era -- Regulatory pathways for 
       biotechnology -- 4. The biopharmaceutical industry in the 
       twenty-first century : titanic challenges ahead -- The 
       biotechnology business crisis -- The biopharmaceutical 
       industry's short-term solutions to the crisis -- 5. 
       Understanding research and development and marketing in a 
       biopharmaceutical company -- Drug discovery -- Drug 
       development -- Regulators -- Intellectual property -- 
       Conducting clinical trials -- Types of drugs -- Generic 
       drugs -- Pricing -- Marketing -- 6. The pharmaceutical 
       regulators -- Causes of the drug approval lag -- FDA and 
       EMEA initiatives to optimize drug approval -- FDA Critical
       Path Initiative -- EMEA's road map to 2010 -- The FDA 
       Amendment Act of 2007 -- Part III: The complexity of 
       innovation. -- 7. The academia : industry relationship -- 
       8. Translating academic innovation into health care 
       products -- Translating basic discoveries into commercial 
       products venture capitalists -- Challenges in translating 
       innovation into commercial products -- Intellectual 
       Property Rights -- Taxpayers' money for innovation and 
       commercial applications -- Important implications for the 
       developing world -- 9. The biotechnology world and its 
       challenges -- 10. Causes of the pharmaceutical crisis -- 
       Drug discovery and development before biotechnology -- 
       Impact of biotechnology in drug discovery and developement
       -- Part IV: Morality and duty on a lonely planet. -- 11. 
       Wealth versus poverty -- Medicines for the developing 
       world: yes, this is our problem -- Bridging the gap? -- 
       Going beyond business -- 12. Social responsibility, 
       governmental role, and nongovernmental organizations -- 
       Part V: Reinventing research and development. -- 13. Time 
       for reorganization -- Reorganization of research and 
       development at the industrial level -- Translational 
       research -- Suggestions for improving the system -- 
       Conclusion: Future trends. 
520    At present, human society is facing a health care crisis 
       that is affecting patients worldwide. In the United States,
       it is generally believed that the major problem is lack of
       affordable access to health care (i.e. health insurance). 
       This book takes an unprecedented approach to address this 
       issue by proposing that the major problem is not lack of 
       affordable access to health care per se, but lack of 
       access to better, safer, and more affordable medicines. 
       The latter problem is present not only in the United 
       States and the developing world but also in countries with
       socialized health care systems, such as Europe and the 
       rest of the industrialized world. This book provides a 
       comparative analysis of the health care systems throughout
       the world and also examines the biotechnology and 
       pharmaceutical industries. Examines the health care 
       structure of the United States, Europe, and the third 
       world, both separately and comparatively offers primary 
       source insight through in-depth interviews with 
       pharmaceutical and health care industry leaders from 
       around the world. Carefully explains, in clear terms, the 
       intricacies of the health care and pharmaceutical system 
       and how these intricacies have led to the current crisis. 
       Offers concrete, comprehensive solutions to the health 
       care crisis. 
650  0 Medical care.|0https://id.loc.gov/authorities/subjects/
       sh85082871 
650  0 Health care reform.|0https://id.loc.gov/authorities/
       subjects/sh93007525 
650  0 Medical ethics.|0https://id.loc.gov/authorities/subjects/
       sh85082929 
650  0 Social medicine.|0https://id.loc.gov/authorities/subjects/
       sh85123973 
650  7 Medical care.|2fast|0https://id.worldcat.org/fast/1013753 
650  7 Health care reform.|2fast|0https://id.worldcat.org/fast/
       952850 
650  7 Medical ethics.|2fast|0https://id.worldcat.org/fast/
       1014081 
650  7 Social medicine.|2fast|0https://id.worldcat.org/fast/
       1122637 
650  7 Medical care.|2homoit|0https://homosaurus.org/v3/
       homoit0001004 
830  0 Elsevier insights.|0https://id.loc.gov/authorities/names/
       no2010053011 
901    MARCIVE 20231220 
935    572409 
948    |d20181012|cLTI|tlti-aup183 
948    |d20171012|cLTI|tlti-aup173 
948    |d20161019|clti|tlti-aup163 
994    C0|bRID